SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is experiencing intense volatility and downward pressure as investors react to a weak sales outlook, with the community actively debating whether the company's turnaround efforts are failing against mounting competition and structural brand decline. Discussion is polarized between those viewing current levels as a long-term value opportunity and those calling for further drops due to concerns over inventory, geopolitical headwinds, and a perceived loss of market relevance.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending as investors weigh an upcoming earnings report against the backdrop of broader cannabis sector volatility, with community debate sharply divided between those betting on a potential post-earnings rally or short squeeze and those citing concerns over dilution and management performance.

Applied Digital Corporation

Applied Digital is experiencing intense volatility as investors weigh the company's long-term potential in AI infrastructure against broader market pressure from geopolitical instability in the Middle East. While bulls highlight upcoming earnings and expectations for new hyperscaler lease agreements as catalysts for a rebound, the stock is facing heavy selling pressure that has the community divided between those aggressively buying the dip and those concerned about the lack of immediate upward momentum.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is currently the subject of intense debate among investors as they weigh the company's long-term potential in the voice AI sector against persistent bearish sentiment and recent downward price pressure. The community is actively tracking high short interest and institutional buying patterns, with many traders looking for a potential squeeze catalyst while others remain cautious due to ongoing macroeconomic and geopolitical volatility.

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF (NASA) is generating intense buzz following its debut as a pure-play space economy fund featuring significant direct exposure to SpaceX. While some traders view the ETF as an accessible, high-volatility opportunity to gain exposure to private space assets, skeptics are actively debating the fund's low assets under management and the transparency of its underlying holdings.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are heavily debating the sustainability of the semiconductor sector's parabolic run, with many actively trading SOXS to hedge against potential instability and potential cooling in AI-related spending. The community remains divided, as some continue to build short positions expecting a correction, while others caution that the sector's resilience in the face of geopolitical tension makes it a dangerous 'widowmaker' for those betting against it.

BARK, Inc. is a dog-centric company, engaged in making products, services, and content for dogs. It operates through the Direct to Consumer and Commerce segments. The Direct to Consumer segment is composed of subscription-based products delivered on a monthly basis. The Commerce segment refers to the sale of BARK products in retail stores and other e-tailers. The company was founded by Matt M. Meeker, Henrik Werdelin, and Carly Strife in 2012 and is headquartered in New York, NY.

BARK Inc - Ordinary Shares - Class A

BARK Inc

BARK is seeing heightened activity as investors weigh the company's recent debt-free status and cost-cutting measures against the upcoming 1-for-20 reverse stock split intended to regain NYSE compliance. While some in the community view the split as a necessary survival step to attract institutional interest, others are skeptical, with active discussions focusing on the potential for volatility, short interest dynamics, and the contrast between current valuation and historical performance.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following the announcement of a clinical development collaboration with Pfizer for the Phase 2 study of ORIC-533, alongside a strategic private placement financing. The community is actively discussing the potential for a short squeeze, citing high short interest and the validation provided by Pfizers direct investment in the company.

Perpetua Resources Corp. is an exploration and development stage company that engages in acquiring mining properties with the intention of exploring, evaluating and placing into production. Its principal business is the exploration, redevelopment, restoration and operation of the Stibnite Gold Project in Idaho, USA. The firm's mineral project is the Stibnite Gold Project, which contains mineral deposits and focuses to explore, evaluate and redevelop all of the deposits known as the Hangar Flats Deposit, West End Deposit and Yellow Pine Deposit, all of which are located within the Stibnite Gold Project. The company was founded in the year 1899 and is headquartered in Donnelly, ID.

Perpetua Resources Corp.

Perpetua Resources is trending following the U.S. Export-Import Bank's decision to advance its $2.7 billion loan for the Stibnite Gold Project to a 25-day congressional notice period, marking a significant milestone before final approval. The community is actively discussing the project's potential to provide a critical domestic supply of antimony for defense and semiconductors, with many investors highlighting the stock's long-term value despite recent volatility.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors anticipate a major catalyst with the pending FDA decision for AXS-05 in Alzheimer's disease agitation, bolstered by strong recent script growth for Auvelity and positive clinical pipeline updates. The community remains focused on the company's progress toward sustained profitability and potential strategic partnerships, frequently debating the stock's long-term valuation relative to its commercial expansion and regulatory milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two h...

Upstream Bio (NASDAQ:UPB) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen lowered shares of Upstream Bio from a "hold" rating to a "sell" rating in a research note on Saturday...

Upstream Bio (NASDAQ:UPB) Downgraded by Evercore to In-Line

Evercore downgraded shares of Upstream Bio from an "outperform" rating to an "in-line" rating and set a $15.00 target price on the stock. in a research note on Friday...

Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data

Upstream Bio outlines Phase 3 plans for verekitug as asthma and CRSwNP data support dosing strategy; shares rise on update.read more...

Upstream Bio (NASDAQ:UPB) Posts Earnings Results, Misses Estimates By $0.06 EPS

Upstream Bio (NASDAQ:UPB - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.06). The company had revenue of $0.67 million for the quarter, compared to analyst...

Upstream Bio (NASDAQ:UPB) Trading Up 11.2% - What's Next?

Upstream Bio (NASDAQ:UPB) Stock Price Up 11.2% - Here's Why...

Upstream Bio (NASDAQ:UPB) Trading 14.4% Higher - Should You Buy?

Upstream Bio (NASDAQ:UPB) Stock Price Up 14.4% - What's Next...

Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Wednesday

Upstream Bio (NASDAQ:UPB) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 11. (View Earnings Report at...

Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) have been given an average rating of "Moderate Buy" by the five analysts that are presently covering the firm, MarketBeat.com reports. One...

Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56%

Upstream Bio (NASDAQ:UPB) reported top-line results from its Phase II VALIANT trial evaluating verekitug in adults with severe asthma, highlighting statistically significant reductions in annualized...

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Upstream Bio Inc.

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

Current Price	$9.00
Prev Close	$8.78
Open	$9.01
Dividend Yield	0.00%
50-Day Moving Average	$15.49
Beta	1.23
Avg. Volume	2.38M
PE Ratio	-3.38

52-Week High	$33.68
52-Week Low	$5.14
Market Capitalization	$477.81M
EPS (Annual)	-$2.66
Price to Book	1.44
Revenue Per Employee	$38,053.33

UPB
Upstream Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest UPB News

UPBUpstream Bio Inc.